Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00563485
NCT00563485TerminatedNot Applicable

Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily in the Successful Rate of Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

Hospital Authority, Hong Kong1 site in 1 country120 target enrollmentStarted: October 1, 2005Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Sponsor
Enrollment
120
Locations
1
Primary Endpoint
Successful rate of Trial Without Catheter (TWOC) at phase 1
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of the study is to compare two alpha blockers, terazosin and doxazosin GITS, in achieving a successful TWOC after AUR due to BPH, among Chinese males in Hong Kong, and in delaying or avoiding a TURP.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
50 Years to — (Adult, Older Adult)
Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Aged 50 or above
  • •Admitted for AUR due to BPH with PVR of 500 ml or more

Exclusion Criteria

  • •Previous history of TURP
  • •Use of alpha blockers within recent 8 months
  • •Renal impairment (serum creatinine >140 umol/l)
  • •Poor premorbid state

Outcomes

Primary Outcomes

Successful rate of Trial Without Catheter (TWOC) at phase 1

Time Frame: At discharge after TWOC (at the end phase one)

Late failure of TWOC of, which is defined as recurrent of AUR or the need of invasive therapy among those who are successful in TWOC in phase 1

Time Frame: From the end of phase one to eight months after successful TWOC (the end of phase 2)

Secondary Outcomes

  • Proportion of subjects with hypotension or symptoms related to hypotension after administration of treatment drug for TWOC(From the time of treatment drug administration to the end of phase 1)
  • Peak flow rate (Qmax), voided volume (Vcomp) and post-voided residue volume (PVR)(At the end of phase I (discharge after TWOC) and at the end of phase 2)

Investigators

Sponsor
Hospital Authority, Hong Kong
Sponsor Class
Other Gov

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
A cross-over study of the effects of terazosin or tamsulosin on the efficacy and sexual function of lower urinary tract symptoms in patients with benign prostatic hyperplasiaDiseases of The genitoruinary system
KCT0004914lsan Univeristy Hospital76
Completed
Phase 3
The effect of Terazosin and Tolterodine in the treatment of double J stent-related urinary symptoms
IRCT20160924029935N2Mashhad University of Medical Sciences80
Completed
Phase 3
Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential HypertensionHypertension
NCT00591578Takeda984
Terminated
Not Applicable
Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow upProstatic HyperplasiaUrinary RetentionAcute Disease
NCT00563654Hospital Authority, Hong Kong48
Recruiting
Phase 2
Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive PatientsHelicobacter Pylori Infection
NCT05933031HK inno.N Corporation381